Research project - Description of molecular alteration targeting in patients with rare cancers: national prospective cohort

Patients with rare cancers represent 25% of all cancer patients. By definition, few treatment options are available for these individuals. This is mainly because clinical trials require a large number of patients with the same type of cancer—something that is rarely possible for most rare cancers.

We have shown that identifying molecular targets through sequencing provides new therapeutic options for 39% of these patients. This enables access to clinical trials of innovative therapies and increases the number of effective treatments for populations with urgent medical needs.

We will analyze data from the France Genomic Medicine 2025 (PFMG2025) program to develop a clinical trial tailored to the most advanced treatments. This relies largely on gene expression analysis and the identification of new therapeutic targets. Such analyses are only possible in France through the PFMG2025 database.